Hollow Brook Wealth Management LLC Buys 88,648 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Hollow Brook Wealth Management LLC raised its stake in Standard BioTools Inc. (NASDAQ:LAB) by 5.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,874,405 shares of the company’s stock after purchasing an additional 88,648 shares during the period. Standard BioTools makes up approximately 1.7% of Hollow Brook Wealth Management LLC’s holdings, making the stock its 18th biggest position. Hollow Brook Wealth Management LLC owned 2.25% of Standard BioTools worth $4,142,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of LAB. EAM Investors LLC acquired a new position in shares of Standard BioTools in the 3rd quarter valued at $1,375,000. Citigroup Inc. acquired a new position in shares of Standard BioTools in the 3rd quarter valued at $550,000. Assenagon Asset Management S.A. acquired a new position in shares of Standard BioTools in the 4th quarter valued at $145,000. Barclays PLC acquired a new stake in shares of Standard BioTools during the 3rd quarter worth about $140,000. Finally, Jump Financial LLC acquired a new stake in shares of Standard BioTools during the 3rd quarter worth about $94,000. 53.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LAB has been the subject of a number of recent analyst reports. Jefferies Financial Group initiated coverage on shares of Standard BioTools in a research report on Thursday, April 4th. They set a “buy” rating and a $3.25 target price for the company. TD Cowen initiated coverage on shares of Standard BioTools in a research report on Tuesday, April 16th. They set a “buy” rating and a $3.50 target price for the company.

Standard BioTools Stock Performance

Shares of Standard BioTools stock remained flat at $2.48 during mid-day trading on Tuesday. 2,748,734 shares of the company were exchanged, compared to its average volume of 2,249,573. The company has a market capitalization of $719.50 million, a P/E ratio of -2.61 and a beta of 1.64. The company has a fifty day simple moving average of $2.61 and a 200-day simple moving average of $2.34. Standard BioTools Inc. has a 1-year low of $1.46 and a 1-year high of $3.16.

Standard BioTools (NASDAQ:LAB) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. The company had revenue of $28.19 million during the quarter, compared to analyst estimates of $28.00 million. On average, equities research analysts expect that Standard BioTools Inc. will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling at Standard BioTools

In related news, Director Casdin Partners Master Fund, L acquired 250,000 shares of the stock in a transaction on Monday, March 4th. The stock was purchased at an average price of $2.57 per share, for a total transaction of $642,500.00. Following the transaction, the director now owns 11,496,525 shares of the company’s stock, valued at approximately $29,546,069.25. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 53.10% of the company’s stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.